Cargando…

Plasma amyloid and tau as dementia biomarkers in Down syndrome: Systematic review and meta‐analyses

Individuals with Down syndrome (DS) are at high risk of developing Alzheimer's disease (AD). Discovering reliable biomarkers which could facilitate early AD diagnosis and be used to predict/monitor disease course would be extremely valuable. To examine if analytes in blood related to amyloid pl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alhajraf, Falah, Ness, Deborah, Hye, Abdul, Strydom, Andre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790908/ https://www.ncbi.nlm.nih.gov/pubmed/31389176 http://dx.doi.org/10.1002/dneu.22715

Ejemplares similares

Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease
por: Startin, Carla M., et al.
Publicado: (2019)

Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers
por: Janelidze, Shorena, et al.
Publicado: (2022)

Dynamics of plasma biomarkers in Down syndrome: the relative levels of Aβ42 decrease with age, whereas NT1 tau and NfL increase
por: Mengel, David, et al.
Publicado: (2020)

Plasma β-amyloid, tau, neurodegeneration biomarkers and inflammatory factors of probable Alzheimer’s disease dementia in Chinese individuals
por: Sun, Qingling, et al.
Publicado: (2022)

Brain amyloid and the transition to dementia in Down syndrome
por: Keator, David B., et al.
Publicado: (2020)

Predicting amyloid PET and tau PET stages with plasma biomarkers
por: Jack, Clifford R, et al.
Publicado: (2023)

Blood Biomarkers for Alzheimer’s Disease in Down Syndrome
por: Montoliu-Gaya, Laia, et al.
Publicado: (2021)

A systematic review and meta-analysis of plasma amyloid 1-42 and tau as biomarkers for Alzheimer’s disease
por: Shanthi, Keerthanaa Balasubramanian, et al.
Publicado: (2015)

Plasma amyloid, tau, and neurodegeneration biomarker profiles predict Alzheimer's disease pathology and clinical progression in older adults without dementia
por: Shen, Xue‐Ning, et al.
Publicado: (2020)

Amyloid‐dependent and amyloid‐independent effects of Tau in individuals without dementia
por: Therriault, Joseph, et al.
Publicado: (2021)

The combined effect of amyloid-β and tau biomarkers on brain atrophy in dementia with Lewy bodies
por: Abdelnour, Carla, et al.
Publicado: (2020)

Amyloid and tau positive mild cognitive impairment: clinical and biomarker characteristics of dementia progression
por: Wei, Hong-Chun, et al.
Publicado: (2021)

Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status
por: Shen, Xue-Ning, et al.
Publicado: (2021)

Predicting amyloid PET positivity using plasma p‐tau181 and other blood‐based biomarkers
por: Kwon, Hyuk Sung, et al.
Publicado: (2023)

Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [(18)F]-Flutemetamol PET Scan Result
por: Westwood, Sarah, et al.
Publicado: (2018)

Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer’s disease in adults with Down syndrome
por: Lleó, Alberto, et al.
Publicado: (2021)

Blood Beta-Amyloid and Tau in Down Syndrome: A Comparison with Alzheimer’s Disease
por: Lee, Ni-Chung, et al.
Publicado: (2017)

Cortical atrophy and amyloid and tau deposition in Down syndrome: A longitudinal study
por: Padilla, Concepcion, et al.
Publicado: (2022)

Amyloid- β and tau deposition influences cognitive and functional decline in Down syndrome
por: Grigorova, Monika, et al.
Publicado: (2022)

Corrigendum: Amyloid and tau positive mild cognitive impairment: clinical and biomarker characteristics of dementia progression
Publicado: (2021)

Plasma phosphorylated tau 181 predicts amyloid status and conversion to dementia stage dependent on renal function
por: Lehmann, Sylvain, et al.
Publicado: (2023)

Assessing Specific Cognitive Deficits Associated with Dementia in Older Adults with Down Syndrome: Use and Validity of the Arizona Cognitive Test Battery (ACTB)
por: Sinai, Amanda, et al.
Publicado: (2016)

Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads
por: Salvadó, Gemma, et al.
Publicado: (2023)

Plasma tau is increased in frontotemporal dementia
por: Foiani, Martha S, et al.
Publicado: (2018)

Increased levels of plasma total tau in adult Down syndrome
por: Kasai, Takashi, et al.
Publicado: (2017)

Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition
por: Risacher, Shannon L., et al.
Publicado: (2019)

Regional binding of tau and amyloid PET tracers in Down syndrome autopsy brain tissue
por: Lemoine, L., et al.
Publicado: (2020)

Distinct Molecular Signatures of Amyloid-Beta and Tau in Alzheimer’s Disease Associated with Down Syndrome
por: Ichimata, Shojiro, et al.
Publicado: (2023)

Serum Amyloid Biomarkers, Tau Protein and YKL-40 Utility in Detection, Differential Diagnosing, and Monitoring of Dementia
por: Wilczyńska, Karolina, et al.
Publicado: (2021)

Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome
por: Strydom, Andre, et al.
Publicado: (2018)

Serum amyloid-p (SAP), a potential biomarker for Down syndrome fetuses prevention in maternal plasma
por: Anagnostopoulos, Athanasios, et al.
Publicado: (2014)

Prediction of Cerebral Amyloid Pathology Based on Plasma Amyloid and Tau Related Markers
por: Chen, Ting-Bin, et al.
Publicado: (2021)

Diagnostic Utility of Selected Serum Dementia Biomarkers: Amyloid β-40, Amyloid β-42, Tau Protein, and YKL-40: A Review
por: Wilczyńska, Karolina, et al.
Publicado: (2020)

Association of Dementia With Mortality Among Adults With Down Syndrome Older Than 35 Years
por: Hithersay, Rosalyn, et al.
Publicado: (2018)

Structural Connectivity in Down Syndrome and Alzheimer’s Disease
por: Saini, Fedal, et al.
Publicado: (2022)

Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study
por: de Wolf, Frank, et al.
Publicado: (2020)

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
por: Gisslén, Magnus, et al.
Publicado: (2009)

Plasma neurofilament light chain: A potential prognostic biomarker of dementia in adult Down syndrome patients
por: Shinomoto, Makiko, et al.
Publicado: (2019)

Amyloid-Tau-Neurodegeneration Profiles and Longitudinal Cognition in Sporadic Young-Onset Dementia
por: Vipin, Ashwati, et al.
Publicado: (2022)

High Levels of β-Amyloid, Tau, and Phospho-Tau in Red Blood Cells as Biomarkers of Neuropathology in Senescence-Accelerated Mouse
por: Piccarducci, Rebecca, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7d46ilfalgupsrenkr5e47nb9p